Skip to main content

Table 5 Linear mixed models of rash, weight loss, and mouth sores/ulcers

From: Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States

 RashaWeight lossbMouth sores/ulcersc
EffectEstimate (SE)P-valueEstimate (SE)P-valueEstimate (SE)P-value
Intercept1.38 (1.065)0.1985.051 (2.337)0.0325.661 (1.795)0.002
Time (months) since diagnosis−0.01 (0.007)0.299− 0.05 (0.016)0.002− 0.06 (0.011)< 0.0001
Treatment: cetuximab±RT (vs. cisplatin±RT)1.45 (0.235)< 0.00010.12 (0.511)0.817−0.24 (0.412)0.567
Treatment* time since diagnosis−0.06 (0.023)0.013−0.04 (0.047)0.3560.03 (0.036)0.375
Age at diagnosis−0.03 (0.009)0.005−0.05 (0.021)0.036−0.05 (0.015)0.001
Male (vs. female)−0.11 (0.179)0.541− 0.31 (0.434)0.480−0.59 (0.291)0.044
White (vs. minority/unknown)−0.01 (0.164)0.946−0.41 (0.387)0.2910.35 (0.268)0.188
Impaired composite performance status (vs. not impaired)0.29 (0.314)0.3630.88 (0.713)0.216−0.53 (0.506)0.291
Weighted index of comorbid conditions−0.01 (0.085)0.8960.02 (0.222)0.927−0.06 (0.141)0.697
Smoking status: current or past (vs. never/unknown/undocumented)−0.20 (0.202)0.3340.24 (0.488)0.6280.04 (0.332)0.912
Alcohol status0.0610.3610.074
 Current or past abuse (vs. never/unknown/undocumented)0.49 (0.212)0.0200.61 (0.506)0.2270.72 (0.346)0.037
 Current or past use (vs. never/unknown/undocumented)0.28 (0.174)0.105−0.02 (0.420)0.9700.09 (0.283)0.750
Stage at start: Stage III (vs. Stage IV)−0.04 (0.154)0.773−0.24 (0.353)0.4930.10 (0.250)0.699
Oral (vs. non-oral)−0.04 (0.414)0.922−0.55 (1.017)0.5880.82 (0.699)0.243
Pharynx (vs. non-pharynx)−0.19 (0.404)0.637−0.32 (0.923)0.7330.66 (0.682)0.336
Larynx (vs. non-larynx)−0.20 (0.428)0.639−0.09 (0.963)0.929−0.41 (0.719)0.567
HPV test results (positive vs. non-positive)0.14 (0.426)0.7400.54 (1.007)0.5911.52 (0.712)0.033
P16 test results (positive vs. non-positive)0.05 (0.181)0.7760.06 (0.512)0.911−0.24 (0.293)0.414
Feeding tube placement (vs. not placed)−0.05 (0.156)0.739−0.14 (0.373)0.7070.42 (0.254)0.099
BMI0.02 (0.012)0.222−0.02 (0.028)0.583−0.01 (0.020)0.777
Insurance0.0420.4750.375
 Only public (vs. only private)0.07 (0.209)0.7380.61 (0.500)0.2260.39 (0.343)0.261
 Both public and private (vs. only private)0.53 (0.196)0.0080.65 (0.459)0.1560.42 (0.320)0.185
 Other/unknown/undocumented (vs. only private)0.19 (0.496)0.7000.63 (1.235)0.6121.03 (0.833)0.215
US Region South (vs. non-South)0.25 (0.706)0.7270.86 (1.428)0.545−1.14 (1.225)0.354
  1. Reference level for each comparison is in parentheses
  2. BMI, body mass index; HPV, human papilloma virus; RT, radiation therapy; SE, standard error; US, United States
  3. aAnalysis is based on 237 patients and 1856 observations
  4. bAnalysis is based on 163 patients and 1303 observations
  5. cAnalysis is based on 237 patients and 1852 observations
  6. *refers to an interaction